Royalty Pharma to Announce Second-Quarter 2021 Financial Results on August 11, 2021
July 19 2021 - 9:00AM
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will
report its second quarter of 2021 financial results on Wednesday,
August 11, 2021 before the U.S. financial markets open. The company
will host a conference call and simultaneous webcast at 8:00 a.m.
Eastern Time that day.
Conference Call Information
The conference call can be accessed live over the phone for U.S.
callers by dialing (833) 519-1253 or for international callers by
dialing +1 (914) 800-3826. The passcode to access the conference
call is 1190246.
A live webcast may be accessed from the “Investors” page of the
company’s website at
https://www.royaltypharma.com/investors/news-and-events/events. A
replay of the conference call and webcast will be archived on the
company's website for at least 30 days.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
not-for-profits through small and mid-cap biotechnology companies
to leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 45 commercial products, including AbbVie and
J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s
Tysabri, J&J’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia,
Novartis’ Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and
Trikafta, and nine development-stage product candidates. For more
information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6772ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024